MOBILIZING NATURE’S DEFENDERS
FOR NEXT-GENERATION THERAPEUTICS
TECHNOLOGY PLATFORM
BACTERIOPHAGE INNOVATION FOR
NEXT-GENERATION MEDICAL HEALTH SOLUTIONS
TECHNOLOGY PLATFORM
PHIOGEN creates breakthrough antimicrobial solutions by using state-of-the-art capture technology and human-like model systems that mimic the complexity of real infections. We select hyper-functional phages that target bacterial vulnerabilities and utilize proprietary machinery to drive evolutionary changes that overcome resistance.
PHIOGEN INC was founded in 2023 to commercialize technology developed at TAILΦR Labs, a personalized phage therapy center of Baylor College of Medicine.
Located at the Texas Medical Center Innovation Hub, PHIOGEN’s experienced team of experts are building on a decade of research in phage biology to develop next generation therapeutics.
Our innovative platform capitalizes on the successes of personalized phage therapy, while our game-changing technology opens the door to a sustainable business model in which we can treat entire patient populations with a single solution.
Born out of innovation, PHIOGEN was founded by Baylor College of Medicine and is supported by BCM Ventures. We have partnered with TAILOR Labs, the US’s first phage discovery and manufacturing center, to bring scientific breakthroughs to patients at a population level. This combination of forces has equipped PHIOGEN with world-class science, unmatched commercial expertise and unlimited clinical access in the world’s largest medical center.
Tailored Antibacterials and Innovative Laboratories for phage (Φ) Research (TAILΦR) is housed in the Texas Medical Center. It is a non-profit initiative delivering personalized and effective treatments for antibiotic-resistant bacterial infections.
PHIOGEN’s unique platform is underpinned by innovative technology and expert insight to generate revolutionary breakthrough in phage biology. The proprietary platform consolidates state-of-the-art technologies inside a single structured research and development process focused on generating commercial solutions.
Amanda Burkardt
Chief Executive Officer
Ms. Amanda Burkardt has over 15 years of experience commercializing technology, consulting, and scientific research both domestically and internationally.
Mayukh Das
Chief Operations Officer
Dr. Mayukh Das has over 19 years of experience developing phage-based products and managing research and development operations inside academia, biotech start-ups and large pharma.
Austen Terwilliger
Clinical Operations Manager
Dr. Austen Terwilliger is an accomplished academic researcher with extensive experience in molecular microbiology, bacterial pathogenesis, wastewater epidemiology, and phage biology.
JUSTIN CLARK
BIOINFORMATICIST
Dr. Justin Clark holds over 15 years of experience as an accomplished molecular biologist, inventor, and bioinformatician.
KEIKO SALAZAR
Principal Scientist
Dr. Keiko Salazar has been working with phages and their pathogenic hosts for over 9 years, starting as a student intern at Sandia National Laboratories.
PAULINE KIM
RESEARCH TECHNICIAN
Ms. Pauline Kim has over 5 years of research laboratory experience in a variety of verticals from chemistry to microbiology.
Soufiane Bel Rhali
RESEARCH TECHNICIAN
Mr. Soufiane Bel Rhali brings over 8 years of extensive research laboratory experience, specializing in microbiology, molecular biology, and bioengineering.
JAMIE BAILEY
Mr. Jamie Bailey has 20 years of accounting and finance experience, leading and overseeing multidisciplinary teams in accounting, planning, treasury and tax functions.
ANTHONY MARESSO
Dr. Anthony Maresso has 20 years experience in genetics, biochemistry, and cell biology and is the Joseph Melnick Chair and Professor in Molecular Virology at Baylor College of Medicine.
JOSEPH PETROSINO
Dr. Joseph Petrosino has over 25 years of experience in microbiology, commercialization, and leadership .
Benjamin Wilhelm
Business Consultant
Oliver Hardcastle
Business Consultant
Our pipeline is focused on delivering novel classes of therapeutics, derived from bacteriophages. The disease targets in our pipeline include several drug-resistant bacteria on the World Health Organization's global priority pathogen list.
Evolved bacteriophages created on our platform have already been successfully administered to patients under emergency use authorization (EUA) provided by the FDA in order to administer rescue treatment in critically-ill patients where antibiotics have failed.
PHIOGEN’s commercialization plan features establishment of partnerships, joint ventures, and licensing arrangements with industry to fuel bacteriophage innovation needs.
Our proprietary technology platform can be deployed on new targets and generate product candidates in an accelerated time period.
If you would like to discuss partnering opportunities, contact us.
PHIOGEN is working with academic research, instituties, and other phage companies to fuel development and accelerate our pipeline.
We are always looking to collaborate and recruit innovation to our platform to help bridge the gap between research and commercialization.
If you are interested in collaborating, contact us.
19th November, 2024
16th October, 2023